Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
280 SEK | 0.00% | -0.36% | +4.87% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The firm trades with high earnings multiples: 28.54 times its 2024 earnings per share.
- The company's enterprise value to sales, at 4.45 times its current sales, is high.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.87% | 8.81B | B+ | ||
+1.45% | 40.51B | A- | ||
-15.94% | 31.67B | B- | ||
+52.66% | 24.62B | A | ||
-14.50% | 15.65B | C | ||
-14.38% | 12.07B | B- | ||
-9.12% | 11.97B | D+ | ||
-42.56% | 11.61B | B | ||
-4.33% | 8.5B | B- | ||
-3.94% | 7.26B | D+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SOBI Stock
- Ratings Swedish Orphan Biovitrum AB